Rhabdomyosarcoma is a tumor of skeletal muscle origin affecting childr
en and young adults. Although relatively undifferentiated, cell lines
derived from this tumor express myogenic regulatory factors and so may
be useful models of abortive myogenic differentiation. In the present
studies, we have determined the effect of increased intracellular cAM
P on proliferation, morphologic differentiation, and expression of myo
genic genes in the prototypic embryonal rhabdomyosarcoma cell line, RD
. Whereas growth in dibutyryl cAMP (dbcAMP), forskolin, or butyrate le
d to morphologic differentiation, growth in dbcAMP inhibited prolifera
tion, while growth in butyrate slowed but did not stop cell division.
Expression of the genes for myogenin and myosin light chain was inhibi
ted by dbcAMP, while butyrate decreased myogenin and increased myosin
light chain transcription. MyoD and MRF4 expression was not altered un
der either condition and no myf5 expression was detected. We also dete
rmined the effects of dbcAMP and butyrate on total protein expression,
as well as on a panel of muscle- and neural-specific proteins using f
unctional assays, immunohistochemistry, and immunoprecipitation. The t
otal protein levels of cells treated with either agent were double tho
se of untreated cells. DbcAMP increased the activity of acetylcholines
terase (AChE) up to 10-fold compared to untreated cells, while butyrat
e had a substantially lesser effect. These increases were due to incre
ased AChE protein synthesis and stability in dbcAMP treated cells, com
pared to butyrate or untreated cells, Finally, cells under all conditi
ons expressed MAP2, a neural-specific microtubule associated protein.
Together, these data suggest that intracellular cAMP levels modulate d
istinct subsets of the myogenic differentiation pathway in rhabdomyosa
rcoma cells. Moreover, they also indicate that RD cells are able to ex
press markers of different cell lineages, which may help explain some
of the paradoxical features of these tumors. (C) 1996 Academic Press,
Inc.